Nanobiotix SA NBTX, +39.38% shares soared 52.1% to a 17-month-high in premarket trade on Monday after the France-based company announced a worldwide licensing and codevelopment agreement with Johnson & Johnson JNJ, +0.14% Janssen Pharmaceutica NV, for its cancer treatment. Nanobiotix is entitled to receive $60 million over the next few years, which includes $30 million for licensing, and $30 for helping to develop NBTXR3, a cancer treatment being evaluated by Johnson & Johnson’s Janssen Pharmaceutica NV. The company is also eligible to receive up to $1.8billion in milestones related to development, sales and regulatory. Nanobiotix stock soared 229.1% in May 5 after the company announced it had entered into final contract negotiations with “major global pharmaceutical companies” to develop NBTXR3. The stock is up 41.1% for the year, according to Friday’s closing price. Meanwhile, the iShares Biotechnology ETF IBB + 1.51%, has fallen 5.3%, and the S&P500 SPX + 0.033%, has risen 14.6%.